Cargando…

AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2

The drug repurposing of known approved drugs (e.g., lopinavir/ritonavir) has failed to treat SARS-CoV-2-infected patients. Therefore, it is important to generate new chemical entities against this virus. As a critical enzyme in the lifecycle of the coronavirus, the 3C-like main protease (3CLpro or M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Bowen, He, Fengming, Liu, Dongpeng, He, Fei, Wu, Tong, Fang, Meijuan, Niu, Zhangming, Wu, Zhen, Xu, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220321/ https://www.ncbi.nlm.nih.gov/pubmed/35740872 http://dx.doi.org/10.3390/biom12060746

Ejemplares similares

Identification and characterization of 7-azaindole derivatives as inhibitors of the SARS-CoV-2 spike-hACE2 protein interaction
por: Wang, Chaojie, et al.
Publicado: (2023)

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
por: Wang, Qian, et al.
Publicado: (2023)

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

AI Aided Design of Epitope-Based Vaccine for the Induction of Cellular Immune Responses Against SARS-CoV-2
por: Mazzocco, Giovanni, et al.
Publicado: (2021)

Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
por: Su, Haixia, et al.
Publicado: (2021)

Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL(pro) covalent inhibitors
por: Stille, Julia K., et al.
Publicado: (2022)

Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity
por: Atkinson, Benjamin N., et al.
Publicado: (2023)

Design and Synthesis of Covalent Inhibitors of FabA
por: Martin, James S., et al.
Publicado: (2023)

Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2
por: Choudhary, Vikram, et al.
Publicado: (2021)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Design, Synthesis and Characterization of Covalent KDM5 Inhibitors
por: Vazquez‐Rodriguez, Saleta, et al.
Publicado: (2018)

A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication
por: Han, Hesong, et al.
Publicado: (2023)

Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL(pro): Inhibition potentials, covalent binding sites and inhibitory mechanisms
por: Xiong, Yuan, et al.
Publicado: (2021)

Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2
por: Li, Qizhang, et al.
Publicado: (2020)

Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases
por: Chen, Zinuo, et al.
Publicado: (2021)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
por: Osipiuk, Jerzy, et al.
Publicado: (2021)

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
por: Lockbaum, Gordon J., et al.
Publicado: (2021)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

Non-covalent SARS-CoV-2 M(pro) inhibitors developed from in silico screen hits
por: Rossetti, Giacomo G., et al.
Publicado: (2022)

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
por: Xiong, Muya, et al.
Publicado: (2022)

Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study
por: Shen, Jian-Xin, et al.
Publicado: (2023)

Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD)
por: Lee, Jai Woo, et al.
Publicado: (2022)

AI-guided pipeline for protein-protein interaction drug discovery identifies a SARS-CoV-2 inhibitor
por: Trepte, Philipp, et al.
Publicado: (2023)

Computer-aided drug design for the pain-like protease (PL(pro)) inhibitors against SARS-CoV-2
por: Gao, Hongwei, et al.
Publicado: (2023)

Establishment and validation of an AI-aid method in the diagnosis of myocardial perfusion imaging
por: Zhang, Ruyi, et al.
Publicado: (2023)

The design and development of covalent protein-protein interaction inhibitors for cancer treatment
por: Cheng, Sha-Sha, et al.
Publicado: (2020)

Adsorption Behavior of a Ternary Covalent Organic Polymer Anchored with SO(3)H for Ciprofloxacin
por: Wang, Zhuoran, et al.
Publicado: (2023)

Design, synthesis, and evaluation of novel benzoylhydrazone derivatives as Nur77 modulators with potent antitumor activity against hepatocellular carcinoma
por: He, Fengming, et al.
Publicado: (2023)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
por: Zain, Rula, et al.
Publicado: (2021)

Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA
por: Shi, Yunfan, et al.
Publicado: (2023)

Computer-Aided and AILDE Approaches to Design Novel 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors
por: Shi, Juan, et al.
Publicado: (2022)

Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro)
por: Wang, Ruyu, et al.
Publicado: (2021)

Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
por: Ge, Rui, et al.
Publicado: (2022)

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
por: Weglarz-Tomczak, Ewelina, et al.
Publicado: (2021)

Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors
por: Seixas, João D., et al.
Publicado: (2020)

The SARS-Cov-2 Proliferation Blocked by a Novel and Potent Main Protease Inhibitor via Computer-aided Drug Design
por: Shayan, Sepideh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7l9qvdkn3oufhapccbqblapa0e